VCM
AXSM icon

Versant Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Versant Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.4K Hold
210
– – ﹤0.01% 1334
2026
Q1 		$35.5K Buy
210
+6
+3% +$1.04K ﹤0.01% 1449
2025
Q4 		$37.3K Hold
204
– – ﹤0.01% 1245
2025
Q3 		$24.8K Buy
204
+203
+20,300% +$22.9K ﹤0.01% 1467
2025
Q2 		$104 Buy
+1
New +$106 ﹤0.01% 2614

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
CA
Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Versant Capital Management's AXSM Position: Q2 2026 in Review

Versant Capital Management held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 210 shares worth $51.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1334.

Versant Capital Management first reported a position in AXSM in Q2 2025 and has held it in 5 quarters since. 38 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Versant Capital Management held 210 shares of Axsome Therapeutics worth $51.4K as of Q2 2026.
  • Versant Capital Management left its Axsome Therapeutics share count unchanged in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1334 holding.
  • Versant Capital Management first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 38 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.